A Dosing Strategy Built on an Assumption the Newer Trials Question
A single patient whose treatment protocol has outlived the evidence it was built on by over a decade. The disagreement is less about him specifically than about how long a superseded assumption can keep running as a standing order before someone asks why.
C.R., a 55-year-old restaurant line cook, presented with melena and lightheadedness after a shift that ended early when he had to sit down twice mid-service. EGD found a 1.2cm duodenal bulb ulcer with adherent clot, successfully treated with endoscopic clipping and epinephrine injection — a lower-risk stigmata than an actively spurting vessel, but still one carrying real rebleeding risk in the first three days, the window every post-hemostasis protocol is built around.
The regimen his team has always used — high-dose bolus followed by continuous IV infusion — was built on the premise that continuous, unbroken acid suppression is what protects clot stability, avoiding any trough where gastric pH might dip low enough to reactivate pepsin and destabilize the clot. That premise made real pharmacokinetic sense when it was established, and it's still a defensible regimen. It is not, however, still the only defensible one. Sachar, Vaidya and Laine's 2014 meta-analysis in JAMA Internal Medicine pooled thirteen randomized trials of patients with exactly C.R.'s category of lesion — active bleeding, a visible vessel, or an adherent clot, all endoscopically treated — and found intermittent dosing, IV or oral, twice or three times daily, non-inferior to continuous infusion on rebleeding, urgent intervention, and mortality. Its authors wrote that guidelines should be revised accordingly. That was over a decade before this admission, and this team's standing order still has not moved. The mechanistic worry behind continuous dosing — that any trough matters — turns out not to be well supported once intermittent dosing was actually tested against it directly, rather than assumed inferior from pharmacokinetic reasoning alone. Cost and nursing time sit underneath the clinical question rather than beside it: continuous infusion ties up a dedicated IV line and requires more frequent pump-rate verification than a scheduled intermittent dose. Those considerations do not decide C.R.'s case on their own, but once the outcome data stop separating the two regimens they are the only thing left that does separate them.
A protocol nobody has revisited since it was written
Continuous infusion is what this unit has always used post-hemostasis, and the rationale behind it — unbroken acid suppression, no trough where gastric pH could dip and reactivate pepsin — is sound pharmacokinetics, not an arbitrary habit.
I'm cautious about changing a protocol that's worked reliably without a clear reason specific to this admission. He's stable, low-risk stigmata, nothing about his case argues for deviating from what we know works.
I don't think the original pharmacokinetic reasoning was wrong when it was written — it made sense at the time.
What's changed is that it's actually been tested directly against intermittent dosing since then. Sachar, Vaidya and Laine's 2014 meta-analysis pooled thirteen randomized trials in patients with high-risk stigmata after endoscopic treatment — his adherent clot is one of the three lesions they enrolled — and found intermittent PPI dosing, IV or oral, two or three times daily, non-inferior to continuous infusion on rebleeding, urgent intervention, and mortality. The trough-matters concern turns out not to hold up once tested directly, rather than assumed from mechanism alone. That evidence predates his admission by a decade, and I don't think "we've always done it this way" is itself a reason to keep going with continuous infusion once outcome-equivalence has been shown.
That's fair — I don't have a reason specific to him to prefer continuous dosing over intermittent, and if the equivalence data are as solid as you're describing, sticking with the old protocol out of habit isn't really a neutral choice either.
I'd support switching him to intermittent IV PPI dosing, and I think it's worth raising with the unit more broadly — not just for his case — given how long this evidence has been sitting unused against our own standing order.
Pantoprazole switched to intermittent IV dosing, twice daily, rather than continued as a continuous infusion, with the Gastroenterologist agreeing to raise the underlying evidence with the broader unit rather than treating this as a one-off deviation from standing protocol.
Agreed cleanly, and notably reframed by the discussion itself — what started as a single patient's dosing question ended with both physicians treating the unit's own unexamined standing order as the more durable issue worth addressing.